Stock Events

Stock Events

Damora Therapeutics 

$28.42
36
+$0.42+1.5% 09:36 Today

Statistics

Day High
28.6
Day Low
27.4
52W High
38.33
52W Low
2.45
Volume
328,154
Avg. Volume
571,011
Mkt Cap
1.73B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30OctExpected
Q3 2025
Q1 2026
Q2 2026
Next
-2.36
-1.7
-1.05
-0.39
Expected EPS
-0.474694
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-209.84MNet Income

Analyst Ratings

44.20Average Price Target
The highest estimate is 50.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DMRA. It's not an investment recommendation.
Apple
2
AAPL
Microsoft
2
MSFT
Realty Income
2
O
Tesla
2
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Madrigal Pharmaceuticals
MDGL
Mkt Cap12.33B
Madrigal Pharmaceuticals is involved in developing therapies for fibrosis, particularly NASH, a direct area of competition with Galecto.
ProQR Therapeutics N.V
PRQR
Mkt Cap323.16M
ProQR Therapeutics works on treatments for fibrosis among other diseases, positioning it as a competitor in the fibrosis space.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences has a strong portfolio in treating fibrotic diseases, making it a major competitor to Galecto.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals has expanded its focus to include fibrosis, directly competing with Galecto's pipeline.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a broad range of treatments including for fibrosis, positioning it as a competitor across multiple areas including those targeted by Galecto.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie has research interests in fibrosis, making it a competitor in the therapeutic area Galecto is targeting.
Novartis
NVS
Mkt Cap292.35B
Novartis has a diversified portfolio that includes treatments for fibrosis, competing with Galecto in the fibrosis therapeutic area.

About

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
Show more...
CEO
Jennifer A. Jarrett
Employees
7
Country
United States
ISIN
KYG2646Y1044

Listings

BOATS
BOATS
GLTO.BOATS
XNAS
US
DMRA

0 Comments

Share your thoughts

FAQ

What is Damora Therapeutics stock price today?▼
The current price of DMRA is $28.42 USD — it has increased by +1.5% in the past 24 hours. Watch Damora Therapeutics stock price performance more closely on the chart.
What is Damora Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Damora Therapeutics stocks are traded under the ticker DMRA.
What is Damora Therapeutics market cap?▼
Today Damora Therapeutics has the market capitalization of 1.73B
When is the next Damora Therapeutics earnings date?▼
Damora Therapeutics is going to release the next earnings report on October 30, 2026.
What were Damora Therapeutics earnings last quarter?▼
DMRA earnings for the last quarter are -0.39 USD per share, whereas the estimation was -0.41 USD resulting in a +5.79% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Damora Therapeutics revenue for the last year?▼
Damora Therapeutics revenue for the last year amounts to 0 USD.
What is Damora Therapeutics net income for the last year?▼
DMRA net income for the last year is -209.84M USD.
How many employees does Damora Therapeutics have?▼
As of September 04, 2026, the company has 7 employees.
In which sector is Damora Therapeutics located?▼
Damora Therapeutics operates in the Health & Wellness sector.
When did Damora Therapeutics complete a stock split?▼
The last stock split for Damora Therapeutics was on August 30, 2024 with a ratio of 1:25.
Where is Damora Therapeutics headquartered?▼
Damora Therapeutics is headquartered in WALTHAM, United States.